Yüklüyor......
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
Even though the prognosis of patients with multiple myeloma is continuing to improve, all patients eventually develop relapsed refractory disease. Several novel therapeutics have been developed in the last few years including the second-generation proteasome inhibitor carfilzomib which has been appr...
Kaydedildi:
| Yayımlandı: | Ther Adv Hematol |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5089326/ https://ncbi.nlm.nih.gov/pubmed/27904737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716667275 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|